4.5 Article

Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates

Journal

VACCINE
Volume 39, Issue 12, Pages 1780-1787

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.01.071

Keywords

Neonates; TB vaccination; BCG; recombinant MVA; Pulmonary immunity; Protection

Funding

  1. NIH [R01 AI058810, 5PO1 HL076100]
  2. Louisiana Vaccine Center - Louisiana Board of Regents [PKSFI-PRS-02]

Ask authors/readers for more resources

This study found that intranasal delivery of MVA-AE can enhance the immune response induced by BCG vaccine, reduce the replication of Mycobacterium tuberculosis in the lungs, and improve the protective efficacy of neonatally-administered BCG against TB infection.
Bacille-Calmette-Guerin (BCG) has variable efficacy as an adult tuberculosis (TB) vaccine but can reduce the incidence and severity of TB infection in humans. We have engineered modified vaccinia Ankara (MVA) strain vaccine constructs to express the secreted mycobacterial proteins Ag85A and ESAT-6 (MVA-AE) and evaluated their immunogenicity and protective efficacy as mucosal booster vaccines for BCG given subcutaneously in early life. Intranasal delivery of MVA-AE to young adult mice induced CD4(+) and CD8(+) T cell responses to both Ag85A and ESAT-6 in lung mucosae. These responses were markedly enhanced in mice that had been primed neonatally with BCG prior to intranasal MVA-AE immunization (BCG/MVA-AE), as evidenced by numbers of pulmonary Ag85A, ESAT-6, and PPD-specific CD4(+) and CD8(+) T cells and by their capacity to secrete multiple antimicrobial factors, including IFNc, IL-2 and IL-17. Moreover, MVA-AE boosting generated multifunctional lung CD4(+) T cells responding to ESAT-6, which were not, as expected, detected in control mice given BCG, and elevated Ag85A-specific circulating antibody responses. After aerosol challenge with M. tuberculosis H37Rv (Mtb), the BCG/MVA-AE group had significantly reduced mycobacterial burden in the lungs, compared with either BCG primed mice boosted with control MVA or mice given only BCG. These data indicate that intranasal delivery of MVA-AE can boost BCG-induced Th1 and Th17-based immunity locally in the lungs and improve the protective efficacy of neonatally-administered BCG against M. tuberculosis infection. (C) 2021 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available